Nexgel Inc. (NXGL) is a development stage biotechnology company that specializes in the discovery, development, and commercialization of innovative therapeutic hydrogels. The company was founded with the core aim of utilizing advanced hydrogel technologies to serve a variety of biomedical applications including wound healing, drug delivery, and bio-adhesion.
The unique technology of Nexgel Inc. revolves around its patented hydrogels - water-swelled, cross-linked networks of flexible polymer chains. The company derives its name from these "next generation" gels, which exhibit impressive versatility. Developed through years of rigorous scientific research, these gels have the advantage of being biocompatible, biodegradable, and capable of maintaining a moist healing environment, which is critical for optimal wound healing.
Nexgel's hydrogel technology harnesses these attributes to develop revolutionary products for a wide range of applications, from wound care to personal care, to specialty health care products. A flagship product is the Skintegrity Hydrogel Wound Dressing, designed for the management of pressure ulcers, partial and full-thickness wounds, and leg ulcers.
Going beyond wound care, Nexgel Inc. also uses its hydrogel technology to develop drug delivery systems. The core idea is that the hydrogel can serve as a vehicle to deliver drugs in a controlled and sustained manner, thereby enhancing their effectiveness and reducing potential side effects.
Apart from the applied research and product development, Nexgel Inc. also actively seeks to collaborate with other entities in the healthcare sector, including research institutions, device manufacturers, and pharmaceutical companies. The objective is to leverage synergies and fuel research that can help bring about improved health outcomes.
Innovative, advanced, and built on a strong foundation of scientific research, Nexgel Inc. continues to harness the power of hydrogel technology to address diverse healthcare challenges. With a focus on skilled research and development and bolstered by a robust portfolio of intellectual property, the company seeks to make meaningful contributions to improving patient care and quality of life.
As with any company in the development stage, Nexgel Inc. operates in a dynamic, competitive, and regulated environment and is subject to various risks and uncertainties. However, through its innovative approach and adherence to the highest standards of research and development, it remains committed to its mission of leveraging hydrogel technology for the betterment of human health.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
NEXGEL Inc. (Nasdaq: NXGL) has successfully regained compliance with Nasdaq's minimum share-price requirement, removing the risk of delisting. The company's stock maintained a closing bid of at least $1 for 10 consecutive trading days through October 23, satisfying Nasdaq Listing Rule 5550(a)(2). This resolution follows a deficiency notice issued in April 2026 when NEXGEL's shares traded below the $1 minimum for 30 consecutive business days.
NEXGEL Inc. (Nasdaq: NXGL) has regained compliance with Nasdaq's minimum share-price requirement, resolving a potential delisting issue. The company's stock maintained a closing bid of at least $1 for 10 consecutive trading days through October 23, satisfying Nasdaq Listing Rule 5550(a)(2). This ensures NEXGEL's continued listing on the Nasdaq Capital Market, removing a regulatory obstacle for the medical technology firm.
NEXGEL, Inc. announced it has regained compliance with Nasdaq's minimum bid price requirement of $1.00, having maintained a closing bid price above this threshold for at least 10 consecutive trading days, culminating on October 23, 2026. This closes the matter previously disclosed on April 22, 2026, and the company's common stock will continue to be listed on The Nasdaq Capital Market. NEXGEL, through its BIONX Surgical division, provides patient-centric medical technology solutions.
NexGel (NASDAQ:NXGL) shares declined by 10.13% after executing a 1-for-20 reverse stock split on October 12, 2026. This type of split is a mechanical adjustment that consolidates shares, typically leading to an immediate increase in stock price without altering market capitalization, but often followed by selling pressure. Separately, Vivakor (NASDAQ:VIVK) experienced an unexplained 30% premarket drop on the same day.